5.30
+5.37%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About OmniAb
From its filings with the US Securities and Exchange Commission
OmniAb is based in Emeryville, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker OABI. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 31 December 2025, it reported revenue of $18.7m and a net loss of $64.8m. At that date it held total assets of $300.9m and shareholders' equity of $267.0m.
OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological IntelligenceTM, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns our interests with the scientific and economic interests of our partners through structured platform license agreements that generally include upfront or annual access fees, service revenue, milestones and royalties on commercial sales.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 9 Oct 2020
- Employees
- 89
- Website
- omniab.com ↗
- Head office
- 5980 HORTON STREET, EMERYVILLE, CA, 94608
- Incorporated in
- DE
- Classification
- Services-Commercial Physical & Biological Research
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. John HigginsChairman of the Board, since 2022$258,040
- Mr. Matthew FoehrPresident, Chief Executive Officer, Director, since 2022$3.6m
- Mr. Kurt GustafsonExecutive Vice President - Finance, Chief Financial Officer$1.7m
- Mr. Charles BerkmanChief Legal Officer, Secretary$1.7m
- Dr. Carolyn BertozziIndependent Director$254,705
- Dr. Jennifer CochranIndependent Director$254,888
- Mr. Steven CrouseIndependent Director
- Dr. Philip GotwalsIndependent Director
- Mr. Steven LoveIndependent Director$248,359
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 39
- Environment
- 38
- Social
- 69
- Governance
- 10
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company operates a unique biological intelligence platform using transgenic animals.
- It offers specialized tools like OmniRat and OmniChicken for antibody generation.
- The firm focuses on developing human therapeutic candidates through genetic modification.
Weaknesses
- The company has a very small workforce of only 89 employees.
- It faces risks associated with being a relatively young public company since 2020.
- The business model relies heavily on specific proprietary animal platforms.
Opportunities
- There is growing industry demand for bispecific antibody applications.
- The company can expand its offerings to address complex therapeutic targets.
- Partnerships in life sciences tools could drive further platform adoption.
Threats
- Competitors in the health care sector may develop alternative discovery methods.
- Regulatory changes could impact the use of transgenic animal models.
- Economic shifts might reduce funding for drug discovery research.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.